Genix Pharmaceuticals Corporation
GENPF
$0.01
-$0.02-53.00%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -50.22% | -21.33% | -25.26% | -28.28% | -43.36% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -99.80% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -87.44% | -21.97% | -27.54% | -28.33% | -0.06% |
| Operating Income | 87.43% | 20.13% | 21.91% | 28.09% | 0.11% |
| Income Before Tax | -158.95% | -1.33% | 42.18% | -72.77% | 104.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -158.95% | -1.33% | 42.18% | -72.77% | 104.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.95% | -1.33% | 42.18% | -72.77% | 104.06% |
| EBIT | 87.43% | 20.13% | 21.91% | 28.09% | 0.11% |
| EBITDA | 87.53% | 20.27% | 22.06% | 28.28% | -123.78% |
| EPS Basic | -157.89% | 0.00% | 45.45% | -85.71% | 104.05% |
| Normalized Basic EPS | 76.00% | 0.00% | 42.86% | -60.00% | -4.17% |
| EPS Diluted | -157.89% | 0.00% | 45.45% | -85.71% | 104.05% |
| Normalized Diluted EPS | 76.00% | 0.00% | 42.86% | -60.00% | -4.17% |
| Average Basic Shares Outstanding | 2.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 2.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |